United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/777,761	02/06/2001	Gerald B. Murphy	P04722US0 4274	
22885 MCKEE VOC	7590 03/23/2007	EXAMINER		
MCKEE, VOORHEES & SEASE, P.L.C. 801 GRAND AVENUE			NAJARIAN, LENA	
SUITE 3200 DES MOINES	, IA 50309-2721		· ART UNIT	PAPER NUMBER
DES MONVES	, 11130307 2721	·	3626	
			MAIL DATE	DELIVERY MODE
			03/23/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
09/777,761	MURPHY, GERALD B.	
Examiner	Art Unit	
Lena Najarian	3626	

•	LAMITHE	Aironn	
	Lena Najarian	3626	
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>16 March 2007</u> FAILS TO PLACE THIS AF	PLICATION IN CONDITION FOR A	ALLOWANCE.	
1. The reply was filed after a final rejection, but prior to or or this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a Not a Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, aff otice of Appeal (with appeal fee) in o ce with 37 CFR 1.114. The reply mi	idavit, or other evider compliance with 37 C	ice, which FR 41.31; or (3)
a) The period for reply expires 3 months from the mailing date	•		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I	ater than SIX MONTHS from the mailing	g date of the final rejecti	on.
Examiner Note: If box 1 is checked, check either box (a) or TWO MONTHS OF THE FINAL REJECTION. See MPEP 7	06.07(f).		
Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as
 The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed 	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	
<u>AMENDMENTS</u>	·	, ,	
 The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below) 	nsideration and/or search (see NO		ecause
(c) They are not deemed to place the application in be appeal; and/or		ducing or simplifying	the issues for
(d) They present additional claims without canceling a	· · · · · · · · · · · · · · · · · · ·	ected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).		liant Amandmant	(DTOL 224)
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324).
 5. Applicant's reply has overcome the following rejection(s) 6. Newly proposed or amended claim(s) would be a non-allowable claim(s). 		timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: <u>NONE</u> . Claim(s) objected to: <u>NONE</u> . Claim(s) rejected: <u>15 and 17-29</u> . Claim(s) withdrawn from consideration: <u>NONE</u> .		ll be entered and an e	explanation of
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
 The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar 	overcome <u>all</u> rejections under appe y and was not earlier presented. S	al and/or appellant fa ee 37 CFR 41.33(d)(ils to provide a 1).
10. The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	ntry is below or attach	ned.
 The request for reconsideration has been considered by <u>See Continuation Sheet.</u> 	it does NOT place the application in	n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08) Paper No(s)	\sim	
13. Other:	JOHN W. HA	rys	
	JOHN W. HA	y é s	

SUPERVISORY PATENT EXAMINER

Continuation of 11.

Applicant's arguments filed 3/16/07 have been fully considered but they are not persuasive. Applicant's arguments will be addressed hereinbelow in the order in which they appear in the response filed 3/16/07.

(1) Applicant argues that O'Brien does not teach an income approach. O'Brien's approach is not an income approach to a marketing plan, it is a price approach.

As per the first argument, the Examiner respectfully submits that O'Brien discloses at p. 4 factors affecting an individual's marketing plan such as attitudes toward price and income risk. As such, it is readily apparent that income is a factor in O'Brien. In addition, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

(2) Applicant argues that O'Brien's approach is based on a producer's self-assessment, including of expected price trends. The result is a marketing plan that can not be relied upon by those providing financing.

As per the second argument, the Examiner respectfully submits that Remley was relied on for the feature of receiving financing (para. 41 of Remley). In response to applicant's argument against the reference individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

(3) Applicant argues that O'Brien's approach does not underwrite pre-selling by a level of crop insurance.

As per the third argument, the Examiner respectfully submits that O'Brien discloses the use of crop insurance (pages 13-14 and 19 of O'Brien). The purpose of the insurance is to protect the proportion of expected production or expected crop revenue (p. 19 of O'Brien). As such, it is readily apparent that O'Brien teaches that the pre-selling is underwritten by the level of crop insurance.

(4) Applicant argues that O'Brien's system does not provide for any type of numeric scoring system or weighting.

As per the fourth argument, the Examiner respectfully submits that Hay was relied on for the features involving scoring. In response to applicant's argument against the reference individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

(5) Applicant argues that O'Brien does not first calculate a level of income, then necessary pre-sell quantities, and then a level of crop insurance. O'Brien suggests determining a level of crop insurance and using that as a guideline for determining pre-sell quantities. Applicant also argues that O'Brien does not determine the minimum level of crop to be sold before determining the amount of crop insurance.

As per the fifth argument, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See In re Keller, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); In re Merck & Co., 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). For example, note page 3 of the Office Action mailed 1/3/07 where the Examiner relied on Hay for the step of determining pre-sell quantities (para. 62 of Hay).